Protalix BioTherapeutics Q1 2026 Financial and Business Update: Key Insights for Investors
Key Highlights
- Elfabrio Milestone: Protalix received a \$25 million milestone payment from Chiesi following European Commission approval of the 2 mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio, a therapy for Fabry disease.
- Revenue Guidance Reaffirmed: The company reaffirmed its 2026 revenue guidance of \$78.0-\$83.0 million, including the \$25.0 million milestone, with Elfabrio sales (excluding milestones) expected to reach \$33.0-\$35.0 million and Elelyso sales projected at \$20.0-\$23.0 million for the year.
- Strong Balance Sheet: As of March 31, 2026, cash, cash equivalents, and short-term bank deposits totaled \$51.1 million, with no outstanding debt or warrants.
- Positive Net Income: Q1 2026 net income was \$18.3 million (\$0.23 per share basic, \$0.22 diluted), a significant turnaround from a net loss of \$3.6 million in Q1 2025.
- Phase 2 RELEASE Study: Enrollment continues for PRX-115, a recombinant PEGylated uricase for uncontrolled gout, with top-line results anticipated in H2 2027. PRX-115 aims to offer improved adherence and durability, targeting immunogenicity challenges.
- Rare Renal Indications: Protalix is advancing PRX-119 (long-acting DNase I) and collaborating with Secarna for RNA-based therapies as part of its strategic focus on rare renal diseases.
- Operational Update: Commercial execution for Elfabrio continues across approved markets, with E4W dosing expected to reduce patient treatment burden and strengthen competitive positioning in Europe.
Detailed Financial Results
- Revenue from Selling Goods: \$7.4 million in Q1 2026, down from \$10.0 million in Q1 2025 due to a timing shift in Pfizer’s Elelyso orders. This was partially offset by \$3.5 million in sales to Chiesi.
- License and R&D Services Revenue: \$26.3 million in Q1 2026, up from \$0.1 million in Q1 2025, primarily driven by the milestone payment from Chiesi.
- Cost of Revenues: \$4.1 million in Q1 2026, a 50% decrease versus \$8.2 million in Q1 2025, reflecting lower sales volumes to Pfizer and Fiocruz.
- R&D Expenses: \$5.4 million in Q1 2026, up 56% from \$3.5 million in Q1 2025, mainly due to the initiation of the PRX-115 Phase 2 RELEASE study.
- SG&A Expenses: \$3.1 million in Q1 2026, up 17% from \$2.6 million in Q1 2025, driven by higher salaries and related expenses.
- Income Taxes: \$2.8 million in Q1 2026, compared to a \$0.1 million benefit in Q1 2025, reflecting taxes on global intangible low-taxed income (GILTI).
Business and Clinical Updates
- Elfabrio for Fabry Disease:
- Market launch and expansion ongoing through Chiesi partnership.
- E4W dosing regimen expected to enhance adoption and treatment flexibility in the EU.
- Global Fabry market projected to reach ~\$3 billion by 2031; Elfabrio targeting 15-20% market share.
- FDA dosing in the US remains at 1 mg/kg every 2 weeks.
- PRX-115 for Uncontrolled Gout:
- Phase 2 RELEASE study (NCT07280156) continues enrollment; top-line results expected H2 2027.
- Potential for best-in-class, long-acting therapy with flexible dosing schedules.
- Preclinical and Strategic Programs:
- Advancing PRX-119 for rare renal indications.
- Collaborating with Secarna for RNA therapeutics to complement ProCellEx platform.
Balance Sheet Strength
Total assets: \$102.3 million as of March 31, 2026 (up from \$82.3 million at year-end 2025).
Total liabilities: \$35.1 million.
Stockholders’ equity: \$67.2 million.
Inventories: \$30.5 million.
No outstanding debt or warrants.
Shareholder-Relevant and Price-Sensitive Insights
- Milestone Revenue: The \$25 million milestone payment materially increased net income and cash reserves, marking a significant, price-sensitive event.
- Guidance Reaffirmation: Management’s confidence in achieving 2026 revenue targets may positively influence investor sentiment.
- Clinical Pipeline Progress: Continued enrollment for PRX-115 is a key value driver; delays or positive trial outcomes could materially move the share price.
- Market Opportunity: Elfabrio’s potential for 15-20% global Fabry market share presents significant upside, especially as the total market is projected to reach \$3 billion by 2031.
- No Debt: The strong balance sheet, with no debt or warrants, reduces financial risk and supports ongoing R&D investment.
- Risks: The report notes risks including regulatory, clinical, operational, and geopolitical uncertainties (especially regional conflict in the Middle East), which could impact operations or share value.
Conference Call & Webcast Details
Investors may listen to the live webcast or call for further details. The conference is scheduled for May 13, 2026, at 8:00 a.m. EDT. Replay will be available for two weeks.
Company Overview
Protalix BioTherapeutics is a biopharmaceutical company specializing in innovative therapeutics for rare diseases, using its proprietary plant cell-based expression system (ProCellEx). The company has commercial partnerships with Pfizer (for Elelyso) and Chiesi Farmaceutici (for Elfabrio), and is developing PRX-115 and PRX-119, targeting major unmet needs in rare disease markets.
Disclaimer
This article contains forward-looking statements based on Protalix management’s estimates and publicly disclosed information. Actual results may differ materially due to risks including, but not limited to, operational, clinical, regulatory, geopolitical, and market factors. Investors should consult the company’s SEC filings and conduct their own due diligence prior to making investment decisions. The information is valid as of the date of publication and is not updated for subsequent events.
